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ABSTRACT 
Aims: Morphine is shown to relieve chronic breathless in chronic obstructive pulmonary disease. 
There are no definitive data in people with heart failure. We aimed to determine the effectiveness 
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and cost-effectiveness of 12 weeks’ morphine therapy for the relief of chronic breathlessness in 
people with chronic heart failure compared with placebo.  
 
Methods: Parallel-group, double-blind, randomised, placebo-controlled, phase III trial of 20mg daily 
oral modified-release morphine conducted in 13 sites in England and Scotland; hospital/community 
cardiology or palliative care out-patients. The primary analysis compared between-group numerical 
rating scale average breathlessness at week 4 using a covariance pattern linear mixed model.  
Secondary outcomes included treatment-emergent harms (worse, or new). 
 
Results: The trial closed early, randomising 45 participants (average age 72 [range 39 to 89] years; 
84% men; 98% New York Heart Association class III). For the primary analysis, the adjusted mean 
difference was 0.26 (95% CI -0.86 to 1.37) in favour of placebo. All other breathlessness measures 
improved in both groups (week 4 change-from-baseline), but by more in those assigned to 
morphine. Neither group was excessively drowsy at baseline or week 4. There were no between-
group differences in quality of life (Kansas) or cognition (Montreal) at any time point. There was no 
exercise-related desaturation and no change between baseline and week 4 in either group.  There 
was no change in vital signs at week 4. The natriuretic peptide measures fell in both groups, but by 
more in the morphine group (morphine 2169 [1092, 3851] pg/mL vs placebo 2851 [1694, 5437]) 
pg/mL. There was no excess serious adverse events in the morphine group. Treatment-emergent 
harms during the first week were more common in the morphine group; all apart from one were ≤ 
grade 2.  
 
Conclusions: We could not answer our primary objectives due to inadequate power. However, we 
provide novel placebo-controlled medium-term benefit and safety data useful for clinical practice 
and future trial design.  Morphine should only be prescribed in this population when other measures 
are unhelpful, and with early management of side-effects.  
 
KEY WORDS: Heart failure; randomized controlled trial; morphine; breathlessness; dyspnea  
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INTRODUCTION 
Although modern medical therapy is successful in improving morbidity and mortality in patients with 
chronic heart failure, for some, breathlessness persists1  despite optimal pharmacological therapy. 
Persisting breathlessness is associated with poorer physical and mental quality of life,2 impaired 
activities of daily living,3 increased unplanned hospital attendance4 and admissions,5 and higher 
mortality.3  Although, non-pharmacological and pharmacological interventions can reduce its impact, 
its importance to patients is often neglected in guidelines and clinical trials.6-8 
 
The perception of breathlessness is processed in brain areas9 rich in opioid receptors.10 Endogenous 
opioids reduce breathlessness whereas the opioid antagonist, naloxone, increases exertion-induced 
breathlessness by blocking the effects of endogenous opioids on the brain.11;12 In people with 
chronic breathlessness due to a range of causes, but mainly chronic obstructive pulmonary disease, 
regular, low dose, modified-release morphine is safe and effective in the short term (7 days).7;13 
However, the evidence is less clear in people with chronic heart failure.14;15 Preliminary data suggest 
that people with chronic heart failure may benefit from morphine given for 3 months. 16 Despite the 
lack of definitive data, morphine is used in clinical practice although there is wide variation in 
willingness to prescribe, dosing and quality of monitoring. Potential problems are: i) patients may be 
denied a helpful medication (due to unfounded17 fears about harms and addiction);18 ii) they may 
have a poorly monitored, suboptimal regime; and iii) there may be no net benefit in the longer term 
(although there is no evidence of tachyphylaxis to date).    
 
We therefore designed BreatheMOR-HF to determine whether morphine therapy given for up to 12 
weeks is superior to placebo for the relief of chronic breathlessness in ambulatory patients with 
chronic heart failure who remained symptomatic despite guideline-recommended medical therapy. 
The trial closed early due to poor recruitment, but collected important medium term placebo-
controlled data especially on toxicity and safety, which we report here.  
 
METHODS 
 
Trial design 
BreatheMOR-HF was a 12 week, parallel group, double-blind, randomised, placebo-controlled, fixed 
dosed, multi-site, phase III trial of 20mg daily oral modified-release morphine measuring 
breathlessness intensity in ambulatory  patients with symptomatic chronic heart failure. 
Participants and setting 
Patients from 13 centres in England and Scotland attending hospital/community cardiology or 
palliative care clinics or hospices, were screened by research nurses in conjunction with the patients’ 
usual clinical team. Eligible participants: i) were aged ≥18 years; ii) had New York Heart Association 
(NYHA) class III/IV symptoms; iii) had either left ventricular systolic dysfunction  defined as left 
ventricular ejection fraction <40%; or left ventricular ejection fraction >40% and left ventricular 
hypertrophy, left atrial dilation or abnormal diastolic function; iv) had N-terminal-pro-B-type 
natriuretic peptide ≥1,000 pg/mL or B-type natriuretic peptide ≥250 pg/mL within the last 3 months; 
v) were on guideline-recommended medical treatment for chronic heart failure and unchanged for 
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≥two weeks; vi) had a glomerular filtration rate ≥30mls/min(/1.73m2) within two weeks; and vii) 
scored ≥grade 2 on the modified Medical Research Council (mMRC) breathlessness scale.  
Optimal medical management for people with reduced left ventricular function was defined as a 
maximally tolerated dose of an inhibitor of the renin-angiotensin system and a beta adrenoceptor 
antagonist and a mineralocorticoid receptor antagonist. People with preserved left ventricular 
function were required only to receive diuretics and treatment for ventricular rate control for atrial 
fibrillation. Patients unable to provide written informed consent or complete study questionnaires, 
had co-existing relevant neoplasia, had used opioids regularly within the last month at a daily dose ≥ 
study dose, or had a documented contra-indication to morphine were excluded.  
Randomisation 
Random allocations (1:1; stratified block randomisation by centre; randomly permuted block sizes of 
2 and 4; investigators blinded to block size) were centrally generated by an online secure service 
(sealed envelope™) following eligibility data entry of consented participants by a site researcher. 
Approvals 
The protocol, amendments and trial documentation were approved by the North West-Liverpool 
Central Research Ethics Committee (ref 14/NW/0277; 01/07/2014). Medicines and Healthcare 
products Regulatory Agency approval was received (11/09/2014). NHS site approvals were obtained 
and the trial was registered (ISRCTN41349358) prior to recruitment.  
Intervention and comparator 
Participants were allocated to capsules of 10mg modified-release morphine (MST® CONTINUS® 
[https://www.medicines.org.uk/emc/product/7666/smpc]) or placebo that were identical in 
appearance, taste and smell. Capsules were to be taken orally twice daily. 
Blinding 
Participants, research team members and clinicians were blind to treatment allocation. Site 
pharmacists received the capsules un-blinded with a tear-off strip to allow blinding at the time of 
dispensing. To prevent un-blinding due to constipation, a laxative (100mg docusate) capsule was 
given twice daily to patients assigned to morphine and an identical placebo to those assigned to the 
placebo-control group.  
Procedures 
Participants’ demographic and clinical details were recorded at baseline prior to randomisation. 
Serum urea, electrolytes and creatinine were measured within 2 weeks of randomisation. Renal 
clearance was assessed using estimated glomerular filtration rate  or calculated (Cockroft and 
Gault).19 The Charlson Comorbidity Score20 and modified-Medical Research Council breathlessness 
scale21 were also recorded at baseline. 
Outcome data were collected at days 2, 4 and 7, and weeks 2, 3, 4, 8 and 12 after randomisation 
during home or clinic visits or by telephone (depending upon the outcomes and patient preference).  
The primary end point was measured at week 4.  Capsules were dispensed at baseline, and at 4 and 
8 weeks. Each time, 56 morphine/placebo and 56 placebo/docusate capsules were dispensed. 
Participants were advised not to drive during the first week and asked to return unused capsules for 
compliance reconciliation.    
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At the end of 12 weeks, participants could choose whether to take open-label morphine following 
the same regimen as the trial but prescribed and monitored by their usual-care clinician. The trial 
was closed early, due to slow recruitment, in May 2018; the last participant completed follow-up in 
August 2018.  
Outcomes 
The primary outcome measure was the average numerical rating scale breathlessness intensity score 
over the previous 24 hours22  assessed at 4 weeks. Table 1 details primary and secondary outcomes.  
Sample size 
Based on our previous data,15 a 1 point difference on the breathlessness scale was chosen to 
demonstrate a minimum clinically important difference. In order to detect this difference between 
the groups at 4 weeks with 90% power at 5% significance, (and assuming a standard deviation of 
2.55, giving a medium effect size of 0.4) 138 patients were required in each group. Allowing for 20% 
attrition, we needed 346 patients (173 to each group). 
Statistical analysis 
Analyses were conducted in Stata v13 (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP) on an intention-to-treat basis.  Statistical tests were two-sided at 
the 5% significance level. Baseline data are summarised overall and by trial arm both by 
randomisation, and separately for participants providing data to the primary end point. No statistical 
comparisons between treatment groups were undertaken on baseline data.  
The primary analysis compared the NRS average breathlessness at week 4 between the morphine 
and placebo groups using a covariance pattern linear mixed model.  The outcomes were numerical 
rating scale at each post-randomisation time point (≤week 12), nested within patients. Scores at 
baseline, trial arm, time point, and a time-by-trial arm interaction were included as fixed-effects with 
participant and site as random-effects. An independent covariance structure for the repeated 
measurements was used as this provided the smallest Akaike’s information criterion.23 
The adjusted mean difference, with its associated 95% confidence interval and p-value, between the 
two groups for the week 4 time point was extracted from the model.  
The secondary outcomes of the Australian-modified Karnofsky Performance Scale, Kansas City 
Cardiomyopathy Questionnaire-12 and Karolinska Sleepiness Scale were similarly analysed.  The 
Epworth Sleep Scale, Montreal Cognitive Assessment, 6-Minute Walk Test and activPAL™ were 
analysed using mixed-effect linear regression to compare the scores at week 4 adjusting for baseline 
score, and site as a random effect (i.e. repeated measures per participant not required to be 
included). 
Data on study drug use is described in Supplementary Table 5, with adverse event data presented by 
trial arm in Supplementary Tables 4a and 4b and on harms in Supplementary Tables 5a and 5b.  
A full cost-effectiveness analysis was originally planned; however, as the study is underpowered, EQ-
5D-5L and health resource use data are summarised descriptively (Supplementary Tables 4a and 4b).
  
This study report uses the CONSORT framework for reporting randomised clinical trials.24  
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RESULTS 
Thirteen sites opened to recruitment and 7 randomised at least one participant. The first participant 
was randomised in June 2016 and recruitment closed in May 2017, by which time 45 patients had 
been recruited and randomised (21 to morphine; 24 to placebo).  
 
Altogether, 386 patients were screened between December 2015 and May 2017 (median 27 per site, 
range 0 to 55), of whom 287 (74%) were ineligible, 53 (14%) declined, and one (0.3%) was eligible 
but the trial closed prior to their randomisation. The most common reasons for ineligibility were 
absence of NYHA functional class III or IV (n=59) and natriuretic peptide plasma concentrations 
below the inclusion criteria (n=34) (Figure 1). 
 
The average age of randomised participants was 72 years (range 39 to 89) and 84% were men (Table 
2.) All but one had NYHA class III symptoms and 78% had mMRC breathlessness grade 3 or 4. 
Baseline characteristics were generally well balanced but those assigned to placebo had more severe 
breathlessness on the mMRC scale (Table 2).  
 
For the primary end-point, the raw mean (standard deviation) scores were 5.3 (2.3) for those 
assigned to morphine (n=20), and 4.6 (2.4) for those assigned to placebo (n=23) (Table 3). The 
adjusted mean difference was 0.26 (95% CI -0.86 to 1.37, p=0.65) in favour of the placebo group 
(Figure 2). No adjusted mean difference of 1 point or more (clinically important difference) was 
observed at 4 weeks between the groups for any NRS item.  
 
From baseline to week 4, breathlessness measures, notably unpleasantness of, and distress due to, 
breathlessness improved in both groups (Table 3). The improvement was greater in those assigned 
to morphine compared to placebo in all but average intensity. All breathlessness scores increased 
further during subsequent weeks in those assigned to morphine but not in those assigned to 
placebo. Subjective global impression of change ratings are presented in Supplementary Table 1. 
 
The median Australian-modified Karnofsky Performance Status was 70 for both groups across all 
time points (Table 4; secondary outcomes). Neither group was excessively sleepy or drowsy at 
baseline or week 4. There were no between-group differences in quality of life (Kansas) or cognition 
(Montreal) at any time point. At week 4, there was a raw mean difference of 1113 steps per day 
favouring the placebo group (activPAL) but of 7.4m in the walk test favouring the morphine group. 
There was no exercise-related desaturation and no change between baseline and week 4 in either 
group.  There was no change in vital signs at week 4. The natriuretic peptide measures fell in both 
groups, but by more in the morphine group (Supplementary Table 2).  
 
Adherence is summarised in Supplementary Table 3.  All but one participant took at least one trial 
capsule. One participant assigned to morphine withdrew the day after randomisation. Three 
participants withdrew fully from the trial (i.e. from treatment and follow-up, Figure 1) and 16 
participants (11 (52.4%) assigned to morphine and 5 (20.8%) assigned to placebo) formally withdrew 
from treatment before the 12 week assessment (median time to treatment withdrawal was 12 
(range 4 to 56) days for morphine and 48 (range 7 to 57) days for placebo. All continued to provide 
7 
 
outcome data.  Participants were asked to take two capsules a day for 84 days; total 168 tablets.  
Estimates of the proportion of tablets taken ranged from 39% to 51% in those assigned to morphine 
and 64% to 83% in those assigned to placebo, depending on an assumption that none or all the pills 
were taken if bottles were not returned. 
 
There were 12 serious adverse events in the morphine group and 15 in the placebo group 
(Supplementary Table 4a). One death occurred in the placebo group. One morphine group 
participant had a marked cognitive decline from baseline at week 4 (25 to 14 MoCA points) which 
coincided with a decline in renal function. The patient fully recovered after stopping morphine. Non-
serious adverse-events (Supplementary Table 4b) were more common in those assigned to 
morphine (32 events) compared to placebo (22 events), although the excess was mainly due to one 
individual assigned to morphine who had nine non-serious events 
 
After randomisation, up to and including week 4, 18 (86%) participants assigned to morphine and 13 
(54%) to placebo reported at least one harm of grade 1 or more, and 10 (48%) and 1 (4.2%), 
respectively, of grade 2 or more (Supplementary Table 5a – up to week 4; Supplementary Table 5b – 
weeks 8 and 12). Constipation, nausea and vomiting were more common in those assigned to 
morphine rather than placebo throughout the trial, but were mainly mild (grade 1). Study 
laxative/placebo was not taken by a substantial number of participants. Treatment emergent 
adverse events during the first week were three times more common in the morphine group and 
were more common in participants with eGFR <54 mls/min (the mean value) (Table 5), but all apart 
from one were grade 2 or less. Most presented by day 4 (see Supplementary Figure 1). Harms by 
grade, treatment group and time point to week 4 are presented in Supplementary Table 
 
Health service use and EQ-5D-5L measures at baseline and follow-up are presented in 
Supplementary Tables 6a and 6b. 
 
DISCUSSION 
 
Main findings/results of the study  
The BreatheMOR-HF trial is the first to provide placebo-controlled data for medium-duration 
modified-release, steady state, low dose, oral morphine for people with persistent breathlessness 
despite guideline-recommended treatments for chronic heart failure. The trial failed to enrol the 
planned number of participants but provides valuable insights into the potential rate and severity of 
morphine-related harm; particularly pertinent given the recent license extension to chronic 
breathlessness (including that due to heart failure) for a sustained release oral morphine preparation 
(Kapanol™) by the Therapeutic Goods Administration in Australia. Constipation, nausea and 
vomiting, albeit mainly mild, were more common in the morphine group, as was study drug 
withdrawal. This highlights the need for early skilful management of morphine-related side-effects 
and careful clinical decision-making regarding prescription of morphine for chronic breathlessness 
given the persisting lack of robust evidence of benefit in this patient population.  
 
Strengths and limitations 
The major limitation of the study is its early termination and consequent lack of power; data can 
only be interpreted as preliminary. Recruitment challenges related to i) some eligibility criteria, 
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particularly the natriuretic peptide threshold, ii) the Research Ethics Committee requirement that 
participants avoided driving for the first week (despite no evidence base25), and iii) delays in opening 
recruitment sites.  Suboptimal adherence to, and withdrawal from, study drug weakened our 
findings. Numbers are too small for a per protocol analysis, but inclusion of data from those who 
stopped study drug may have diluted benefit experienced by those who tolerated morphine.  
 
The major strength is the double-blind, placebo-controlled design and trial duration. Data quality 
and completion rates (apart from physical activity and exercise tolerance) were very high, with 
minimal full study withdrawal. In addition, our study recruited the targeted population with 
advanced disease.  
 
What this study adds 
Although participants had advanced disease, there were no excess serious adverse events in the 
morphine group. We found no respiratory depression consistent with a recent systematic review 
and meta-analysis.17;18  
 
The reports of (mainly mild) constipation, nausea and vomiting in the morphine group are similar to 
other published reports of low dose morphine for breathlessness14;15;26;27 but are nonetheless 
important. In this study protocol, anti-emetics were not co-prescribed from study drug initiation in 
the same way as laxatives, but given in response to emergent nausea. It is possible that patients with 
heart failure and renal dysfunction may be susceptible to nausea as blood brain barrier permeability 
is increased, at least in acute kidney injury,28 and initial co-prescription might be useful. 
Recommendations for management of morphine-related side-effects are available but may be 
unfamiliar to non-palliative care or non-pain specialists.29  
 
Impaired cognition is cited as a particular fear of morphine treatment by both patients and 
clinicians,30 but we found no excess sleepiness or cognitive impairment in the morphine group apart 
from one patient with deterioration in renal function. We saw a reduction in daily steps with 
morphine but no increase in daytime sleepiness. The walk distance increased further in the 
morphine group, but there was a high proportion of missing data making interpretation difficult. The 
lack of desaturation on exertion is reassuring and consistent with previous findings.17  
 
In the morphine group all breathlessness measures, apart from week 4 average breathlessness, had 
greater improvement from baseline than the placebo group. Improvements in all breathlessness 
measures were sustained or improved further by week 8 and 12 in the morphine group and reached 
clinically important differences. Further improvement beyond week 4 was not seen in the placebo 
group in any breathlessness measure and none reached clinical significance. At baseline, the 
breathlessness scores were on average worse in the morphine group than control by around a 
clinically important difference (1 point) for each measure and so may represent a group more likely 
to respond to morphine.31 However, such findings can only be interpreted as a preliminary signal of 
benefit. 
 
Implications for clinical practice and research 
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Morphine should only be prescribed in people with heart failure when other measures have not 
helped, and only with early recourse to management of potential side-effects. Fears of serious harm 
are unsubstantiated. 
 
The observed pattern of improvement in breathlessness measures in the morphine group suggests 
that an adequately sized trial would be useful. Lessons learnt from recruitment and attrition 
challenges should be incorporated in a new study. A dose titration step should be included and an 
initiation side-effect management plan put in place. The eligibility criterion relating to natriuretic 
peptide should be removed, but included as a secondary outcome in view of the observation that 
levels reduced by more in the morphine group; a finding seen in previous work and the significance 
of which is unknown.14 The extensive trials unit support required to navigate the complex 
governance required to open multiple recruitment sites needs to be planned for.   
 
The observed standard deviation of the primary outcome measure was lower than the anticipated 
2.55 in each group at all time-points; the correlation between the baseline and week 4 measures of 
the primary endpoint was 0.67. A recalculated sample size of 150 patients would provide 80% power 
to detect the same planned difference, assuming a standard deviation of 2.55, 5% significance level, 
a conservative correlation of 0.65 between the baseline and week 4 measures, and 20% attrition. 
 
 
CONCLUSIONS 
We were unable to answer our primary objectives due to inadequate power. However, we provide 
novel preliminary placebo-controlled data relating to the benefit and safety of medium-term oral 
modified-release morphine which will help inform clinical practice and the design of a future trial.  
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Figure 1: CONSORT flow diagram of participant through the BreatheMOR-HF trial 
 
Figure 2: Mean average breathlessness by randomised group and time point as measured on a 
numerical rating scale from 0 (no breathlessness) to 10 (worst imaginable breathlessness) adjusted 
for baseline NRS 
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Table 1: Overview of primary and secondary outcomes 
Primary outcome Average breathlessness over the previous 24 hours (Baseline, D2, D4, D7, W2, W3, W4 
[primary time point], W8 and W12) 
o 0-10 (11 point) NRS22 
o 0 = none to 10 = worst imaginable  
Other 
breathlessness 
assessments 
Intensity of worst breathlessness over the previous 24 hours; Distress due to 
breathlessness over the previous 24 hours; Unpleasantness of breathlessness over the 
previous 24 hours (Baseline, D2, D4, D7, W2, W3, W4, W8 and W12) 
o 0-10 (11 point) NRS22 
o 0 = none to 10 = worst imaginable  
 Global impression of change (W4)32 
o Subjective measure of response to treatment 
o Participants asked if their breathlessness has changed and by how much using a 
verbal rating scale 
Related symptoms  Average pain over previous 24 hours (Baseline, D2, D4, D7, W2, W3, W4, W8 and W12) 
o 0-10 (11 point) NRS33 
o 0 = no pain to 10 = worst imaginable pain 
Epworth Sleepiness Scale (ESS; Baseline and W4)34 
o Screening tool for sleep-disordered breathing 
o Specifically distinguishes reports of daytime dozing behaviour from fatigue and 
drowsiness/sleepiness  
o Scores between 0 to 24 
o Higher scores indicate excessive sleepiness (11-12 mild; 13-16 moderate; >16 
severe) 
Functional and 
performance status 
6 minute walk test (6MWT; Baseline and W4)35  
o Recorded distance walked in metres, and O2 saturation at rest and post test 
Physical activity monitoring (activPAL™ step count; Baseline and W4)36 
o activPAL™ worn for 7 days at baseline prior to randomisation and for 7 days prior 
to week 4  
o Discriminates between sedentary, upright and stepping activities  
o Average daily step count documented 
Montreal Cognitive Assessment (MoCA; Baseline and W4. Shortened telephone-based 
MoCA administered at D4 and D7)37 
o 30-item questionnaire assessing cognitive function  
o Scores between 0 and 30; ≥ 26 implies no cognitive impairment (telephone 
version scored 0 to 16) 
o Items that could be administered by phone assessed on days 4 and 7 
New York Heart Association class (NYHA; Baseline, W4 and W12)38 
o Four classes based on symptoms (I, II, III, IV) 
o Class IV denotes worst symptom status 
Australia-modified Karnofsky Performance Status (AKPS; Baseline, W4 and W12)39  
o Validated variant of Karnofsky Performance Status 
o Scored 0 to 100 in increments of 10 assigned to participants based on ability to 
perform activities of daily living; higher scores imply better function 
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Quality of life Kansas City Cardiomyopathy Questionnaire-short form (KCCQ-12; Baseline, W4 and 
W12)40 
o 12-item, self-administered instrument quantifying physical function, symptoms 
(frequency, severity and recent change), social function, self-efficacy and 
knowledge, and quality of life 
o Combined single, overall summary score between 0 and 100  
o Higher scores indicate better functioning, fewer symptoms, and better disease-
specific quality of life 
Harms* Opioid-relevant symptoms during each assessment using criteria established by the 
National Cancer Institute (version 4.03) and graded accordingly (Baseline, D2, D4, D7, 
W2, W3, W4, W8 and W12)41 
o Constipation  
o Confusion  
o Nausea 
o Vomiting  
o Memory impairment 
o Cognitive impairment  
Karolinska Sleepiness Scale (KSS; Baseline, D2, D4, D7, W2, W3 and W4)42  
o 9-point Likert scale of the patient’s level of drowsiness (1=very alert to 9=very 
sleepy)  
Health economic 
assessment 
EuroQoL EQ-5D-5L (Baseline, W4, W8 and W12)43 
o self-administered, validated measure of health status  
o 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression 
o 5 level (level 1= no problems, level 2 = slight problems, level 3 = moderate 
problems, level 4 = severe problems, 5 = unable [or extreme]) and a visual 
analogue self-rating scale 
Health service use (Baseline, W4, W8 and W12) 
o Participants recall specified service use over the past 4 weeks  
Clinical 
assessments 
Standard examination (Baseline and W4)  
o resting pulse rate, and blood pressure,  
o resting respiratory rate  
o pulse oximetry  
N-terminal proBNP (B-type Natriuretic Peptide) measurement (Baseline and W4) 
o For sites with access to this test as part of clinical practice 
Dose of “as required” immediate release opioid for breathlessness (W4 and W12) 
o Patient diary: if, when, and the dose of any “as required” dose of immediate 
release opioid solution taken for breathlessness.  
 * Harms. Known opioid-related adverse events were measured at baseline and during follow-up.  
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Table 2: Baseline characteristics by randomised group, as randomised and as included in the primary 
outcome analysis 
Characteristica 
As randomised As analysed 
Morphine 
(n=21) 
Placebo 
(n=24) 
Morphine 
(n=20) 
Placebo 
(n=23) 
Sex 
  Male 
  Female 
 
18 (85.7) 
3 (14.3) 
 
20 (83.3) 
4 (16.7) 
 
17 (85.0) 
3 (15.0) 
 
20 (87.0) 
3 (13.0) 
Age, years 74.4 (6.0) 70.1 (14.0) 74.1 (6.0) 71.5 (12.6) 
Ethnicity 
  White 
 
21 (100.0) 
 
24 (100.0) 
 
21 (100.0) 
 
24 (100.0) 
NYHA Class 
  III 
  IV 
 
20 (95.2) 
1 (4.8) 
 
24 (100.0) 
0 (0.0) 
 
19 (95.0) 
1 (5.0) 
 
23 (100.0) 
0 (0.0) 
Resting pulse rate 
(per minute) (radial) 
 
77.0 (24.0) 
 
77.0 (11.2) 
 
76.8 (24.6) 
 
77.1 (11.4) 
Resting systolic 
blood pressure, 
mmHg 
 
 
119.8 (24.2) 
 
 
116.1 (14.5) 
 
 
121.3 (23.8) 
 
 
116.4 (14.8) 
Resting diastolic 
blood pressure, 
mmHg 
 
 
69.4 (12.3) 
 
 
68.0 (11.6) 
 
 
70.2 (12.1) 
 
 
68.7 (11.2) 
Resting respiratory 
rate (per minute) 
 
17.9 (6.8) 
 
15.6 (4.4) 
 
18.2 (6.8) 
 
15.4 (4.4) 
Pulse Oximetry, % 97.1 (2.1) 96.7 (1.6) 97.1 (2.1) 96.7 (1.7) 
mMRC gradeb 
  0 
  1 
  2 
  3 
  4 
 
0 (0.0) 
0 (0.0) 
7 (33.3) 
11 (52.4) 
3 (14.3) 
 
0 (0.0) 
0 (0.0) 
3 (12.5) 
21 (87.5) 
0 (0.0) 
 
0 (0.0) 
0 (0.0) 
7 (35.0) 
10 (50.0) 
3 (15.0) 
 
0 (0.0) 
0 (0.0) 
3 (13.0) 
21 (87.0) 
0 (0.0) 
eGFR, mls/min 53.0 (18.2) 62.2 (21.4) 53.9 (18.2) 61.8 (21.8) 
NTproBNPc, pg/mL 
BNP, pg/mL 
 
N=20, 2963 
(1883, 4743) 
N=1, 528 (-) 
N=22, 2587  
(1436, 4636) 
N=2, 844 (-) 
N=19, 2843  
(1860, 4230) 
N=1, 528 (-) 
N=21, 2646  
(1761, 4636) 
N=2, 844 (-) 
Charlson 
Comorbidity Index 
 
6.7 (1.4) 
 
6.2 (2.3) 
 
6.7 (1.5) 
 
6.4 (2.0) 
a Continuous data is presented as mean (SD) and categorical data as n (%);  
b 0=Not troubled by breathlessness except on strenuous exercise, 1=Short of breath when 
hurrying or walking up a slight hill, 2=Walks slower than contemporaries on the level because 
of breathlessness, or has to stop for breath when walking at own pace, 3=Stops for breath 
after about 100m or after a few minutes on the level, 4=Too breathless to leave the house, or 
breathless when dressing or undressing;  
c NTproBNP conducted by certain sites only; data presented as median and Interquartile range 
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Table 3: Raw NRS summary scores for breathlessness by randomised group and time point, with 
adjusted mean difference between the groups at primary time point of 4 weeks. 
NRS  
[0 (best) – 10 (worst)] 
N, Mean (SD) 
Time 
point 
Morphine 
(n=21) 
Placebo 
(n=24) 
Total 
(n=45) 
Adjusted mean 
difference at W4 
(95% CI) 
p-value 
How bad has your 
breathlessness felt on 
average over the past 
24 hours? 
Baseline 21, 5.8 (2.0) 24, 5.0 (1.9) 45, 5.3 (1.9) 
0.26 (-0.86, 1.37) 
p=0.65 
D2 20, 4.7 (2.1) 24, 4.7 (1.6) 44, 4.7 (1.8) 
D4 20, 4.4 (2.1) 24, 4.5 (1.7) 44, 4.5 (1.9) 
D7 20, 4.6 (2.5) 24, 4.7 (1.7) 44, 4.6 (2.1) 
W2 20, 4.8 (2.4) 24, 4.7 (2.0) 44, 4.8 (2.1) 
W3 20, 4.7 (2.4) 23, 4.0 (2.2) 43, 4.3 (2.3) 
W4 20, 5.3 (2.3) 23, 4.6 (2.4) 43, 4.9 (2.4) 
W8 20, 4.9 (2.4) 23, 4.9 (2.1) 43, 4.9 (2.2) 
W12 20, 4.6 (2.5) 22, 5.0 (2.2) 42, 4.8 (2.4) 
How bad has your 
breathlessness felt at 
its worst over the past 
24 hours? 
Baseline 21, 7.2 (2.4) 24, 6.2 (1.9) 45, 6.7 (2.2) 
0.15 (-1.13, 1.44) 
p=0.82 
D2 20, 5.2 (2.1) 24, 5.2 (2.2) 44, 5.2 (2.1) 
D4 20, 4.5 (2.5) 24, 5.1 (2.5) 44, 4.8 (2.5) 
D7 20, 5.2 (2.8) 24, 5.3 (2.3) 44, 5.3 (2.5) 
W2 20, 5.3 (2.5) 24, 5.1 (2.0) 44, 5.2 (2.2) 
W3 20, 5.0 (2.3) 23, 4.4 (2.5) 43, 4.7 (2.4) 
W4 20, 5.9 (2.5) 23, 5.3 (2.6) 43, 5.6 (2.5) 
W8 20, 6.0 (2.8) 23, 5.3 (2.5) 43, 5.6 (2.6) 
W12 20, 5.1 (2.8) 22, 5.5 (2.0) 42, 5.3 (2.4) 
How unpleasant has 
your breathlessness 
been on average over 
the past 24 hours? 
Baseline 21, 5.6 (2.4) 24, 4.5 (2.0) 45, 5.0 (2.2) 
-0.15 (-1.48, 1.17) 
p=0.82 
D2 20, 4.3 (2.2) 24, 4.0 (1.8) 44, 4.1 (2.0) 
D4 20, 4.0 (2.2) 24, 3.8 (2.1) 44, 3.9 (2.1) 
D7 20, 4.4 (2.8) 24, 3.8 (2.1) 44, 4.1 (2.5) 
W2 20, 4.3 (2.7) 24, 4.4 (2.2) 44, 4.4 (2.4) 
W3 19, 3.8 (2.1) 23, 2.9 (2.2) 42, 3.3 (2.2) 
W4 20, 4.7 (2.8) 23, 4.3 (2.1) 43, 4.4 (2.4) 
W8 20, 4.3 (2.6) 23, 4.1 (2.5) 43, 4.2 (2.6) 
W12 20, 4.3 (3.0) 22, 4.3 (2.6) 42, 4.3 (2.7) 
How much distress 
has your 
breathlessness caused 
you on average over 
the past 24 hours?  
Baseline 21, 5.7 (2.4) 24, 4.1 (2.3) 45, 4.8 (2.5) 
-0.55 (-1.99, 0.88) 
p=0.45 
D2 20, 3.3 (2.5) 24, 3.3 (2.1) 44, 3.3 (2.2) 
D4 20, 2.7 (2.5) 24, 3.1 (2.7) 44, 2.9 (2.6) 
D7 20, 3.5 (3.0) 24, 3.3 (2.3) 44, 3.4 (2.6) 
W2 20, 3.8 (3.2) 24, 3.1 (2.6) 44, 3.4 (2.9) 
W3 20, 3.3 (2.7) 22, 2.8 (2.4) 42, 3.0 (2.5) 
W4 20, 4.2 (3.3) 23, 3.8 (2.6) 43, 4.0 (2.9) 
W8 20, 4.2 (3.1) 23, 3.6 (2.6) 43, 3.8 (2.8) 
W12 20, 3.8 (2.9) 22, 4.0 (2.4) 42, 3.9 (2.6) 
How much pain have 
you had on average 
over the past 24 
hours?  
Baseline 21, 1.9 (3.1) 24, 1.2 (2.1) 45, 1.5 (2.6) 
-0.05 (-1.29, 1.20) 
p=0.94 
D2 20, 1.3 (2.4) 24, 1.3 (2.0) 44, 1.3 (2.1) 
D4 20, 1.3 (2.5) 24, 0.9 (1.7) 44, 1.0 (2.1) 
D7 18, 0.8 (1.9) 24, 0.7 (1.6) 42, 0.8 (1.7) 
W2 20, 1.3 (2.5) 24, 0.8 (1.4) 44, 1.0 (2.0) 
W3 20, 0.9 (1.9) 23, 1.0 (1.6) 43, 0.9 (1.7) 
16 
 
W4 20, 1.5 (2.8) 23, 1.1 (1.9) 43, 1.3 (2.3) 
W8 19, 1.9 (3.4) 23, 1.8 (3.0) 42, 1.8 (3.1) 
W12 20, 2.0 (3.3) 22, 0.9 (2.0) 42, 1.4 (2.8) 
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Table 4: Other secondary outcome scores by randomised group and time point 
Outcome 
Morphine 
(n=21) 
Placebo 
(n=24) 
Total 
(n=45) 
Adjusted mean 
difference at 
W4 
(95% CI) 
p-value 
Australia - Modified Karnofsky Performance Status, [10 (comatose) -100 (normal)] 
Baseline 21 70 (60, 80) 24 70 (60, 70) 45 70 (60, 70) -2.1 (-7.0, 2.8) 
p=0.40 Week 4 20 70 (60, 75) 22 70 (70, 70) 42 70 (70, 70) Week 12 22 70 (60, 80) 20 70 (60, 80) 42 70 (60, 80) 
Cardiomyopathy Questionnaire (Kansas City), [1 (extremely limited) – 100 (not limited)] 
Baseline 21 36.6 (14.7) 24 40.2 (11.9) 45 38.5 (13.2) -2.7  
(-9.7, 4.3) 
p=0.44 
Week 4 20 37.2 (16.0) 22 44.1 (12.9) 42 40.8 (14.7) 
Week 12 20 42.2 (22.0) 22 42.3 (17.7) 42 42.2 (19.6) 
Epworth Sleepiness Scale, [0-24; higher score = greater sleepiness] 
Baseline 21 9.6 (4.1) 24 9.5 (4.8) 45 9.6 (4.5) 1.3 
(-0.8, 3.5) 
p=0.23 
Week 4 20 10.6 (5.2) 22 9.4 (4.3) 42 10.0 (4.8) 
Karolinska Sleepiness Scale, [1=very alert - 9=very sleepy] 
Baseline 21 3.0 (1.5) 24 3.3 (1.6) 45 3.2 (1.5) 
0.3 
(-0.5, 1.2) 
p=0.45 
Day 2 20 3.8 (1.7) 24 3.4 (1.2) 44 3.6 (1.4) 
Day 4 20 3.8 (1.9) 24 3.8 (1.9) 44 3.8 (1.8) 
Day 7 20 4.6 (2.5) 24 3.5 (1.7) 44 4.0 (2.2) 
Week 2 20 3.2 (1.4) 24 3.5 (1.9) 44 3.4 (1.7) 
Week 3 20 3.1 (1.4) 23 3.2 (1.8) 43 3.1 (1.6) 
Week 4 20 3.3 (1.5) 23 3.0 (1.6) 43 3.2 (1.5) 
Montreal Cognitive Assessment, [0-30 (0-16 phone version); lower scores = greater cognitive 
impairment] 
Baseline 21 25.1 (1.9) 24 25.4 (3.1) 45 25.2 (2.6) 
-0.5  
(-2.2, 1.1) 
p=0.53 
Day 4 (phone version) 19 14.1 (1.3) 21 14.3 (1.9) 40 14.2 (1.6) 
Day 7 (phone version) 18 14.2 (1.1) 23 14.7 (1.3) 41 14.5 (1.2) 
Week 4 20 26.2 (3.3) 21 26.8 (2.3) 41 26.5 (2.8) 
Six minute walk test, Distance walked (metres) 
Baseline 18 153 (105, 
273) 
24 179 (133, 
255) 
42 160 (120, 
270) 18.7  (-48.8, 86.3) 
p=0.59 Week 4 13 169 (120, 250) 
17 165 (90, 
270) 
30 167 (104, 
270) 
O2 saturation at rest (%)        
Baseline 18 97 (96, 99) 24 97 (95, 98) 42 97 (96, 98) -0.7  
(-1.8, 0.4) 
p=0.23 
Week 4 13 96 (95, 98) 16 97 (96, 98) 29 97 (95, 98) 
O2 saturation at end (%)        
Baseline 18 98 (97, 98) 24 97 (96, 99) 42 98 (97, 99) -0.2  
(-1.3, 0.9) 
p=0.74 
Week 4 13 97 (96, 98) 16 97 (96, 99) 29 97 (96, 98) 
activPAL™, Average steps per day 
Baseline 20 2503 (976, 
3700) 
22 2207 (473, 
3183) 
42 2315 (589, 
3445) 
18 
 
Week 4 19 1943 (361, 
2975) 
17 2717 
(1744, 
3143) 
36 2259 
(1061, 
3063) 
-728.2  
(-1438.5, -17.8) 
p=0.05 
Data are N, mean (SD) or N, median (IQR) 
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 Table 5: Number of participants experiencing a treatment-emergent harm within the first week of 
follow-up, stratified by median baseline eGFR of 54 mls/min: 
 Grade ≤2 Grade ≥3 
 Morphine Placebo Morphine Placebo 
 eGFR≤54 
(n=14) 
eGFR>54 
(n=7) 
eGFR≤54 
(n=9) 
eGFR>54 
(n=15) 
eGFR≤54 
(n=14) 
eGFR>54 
(n=7) 
eGFR≤54 
(n=9) 
eGFR>54 
(n=15) 
Confusion 0 (0.0) 1 (14.3) 0 (0.0) 1 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Constipation 9 (64.3) 5 (71.4) 0 (0.0) 2 (13.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Vomiting 5 (35.7) 1 (14.3) 1 (11.1)   0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Nausea 9 (64.3) 3 (42.9) 1 (11.1) 2 (13.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Memory 
impairment 1 (7.1) 1 (14.3) 0 (0.0) 1 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Cognitive 
disturbance 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 
At least one 11 (78.6) 6 (85.7) 1 (11.1) 5 (33.3) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 
 
 
Supplementary Table 1: Global Impression of Change relating to breathlessness, at week 4 (valid 
data provided by 41 participants) 
Global Impression of 
Change 
Morphine 
(n=20) 
Placebo 
(n=21) 
Total 
(n=41) 
Is your breathing    
Worse 1 (5.0) 1 (4.8) 2 (4.9) 
About the same 13 (65.0) 9 (42.9) 22 (53.7) 
Better 6 (30.0) 11 (52.4) 17 (41.5) 
If better…    
If your breathing is 
better, how much 
better is your 
breathing? 
N=6 N=11 N=17 
Almost the same, 
hardly any better at all 
0 (0.0) 0 (0.0) 0 (0.0) 
A little better 3 (50.0) 4 (36.4) 7 (41.2) 
Somewhat better 1 (16.7) 2 (18.2) 3 (17.7) 
Moderately better 0 (0.0) 2 (18.2) 2 (11.7) 
A good deal better 2 (33.3) 2 (18.2) 4 (23.5) 
A great deal better 0 (0.0) 1 (9.1) 1 (5.9) 
A very great deal 
better 
0 (0.0) 0 (0.0) 0 (0.0) 
If your breathing is 
worse, how much 
worse is your 
breathing? 
N=1 N=1 N=2 
Almost the same, 
hardly any worse at all 
0 (0.0) 0 (0.0) 0 (0.0) 
A little worse 0 (0.0) 0 (0.0) 0 (0.0) 
Somewhat worse 0 (0.0) 1 (100.0) 1 (50.0) 
20 
 
Moderately worse 0 (0.0) 0 (0.0) 0 (0.0) 
A good deal worse 1 (100.0) 0 (0.0) 1 (50.0) 
A great deal worse 0 (0.0) 0 (0.0) 0 (0.0) 
A very great deal 
worse 
0 (0.0) 0 (0.0) 0 (0.0) 
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Supplementary Table 2: Clinical assessments and NYHA class at week 4 by randomised group 
Characteristic Morphine (n=21) 
Placebo 
(n=24) 
Total 
(n=45) 
NYHA Class 
  II 
  III 
  IV 
  Missing 
 
1 (4.8) 
18 (85.7) 
1 (4.8) 
1 (4.8) 
 
1 (4.2) 
21 (87.5) 
0 (0.0) 
2 (8.3) 
 
2 (4.4) 
39 (86.7) 
1 (2.2) 
3 (6.7) 
Resting pulse rate 
(per minute) (radial) 
 
69.5 (11.8) 
 
72.1 (9.6) 
 
70.9 (10.6) 
Resting systolic 
blood pressure, 
mmHg 
 
 
109.4 (16.4) 
 
 
111.5 (19.3) 
 
 
110.5 (17.8) 
Resting diastolic 
blood pressure, 
mmHg 
 
 
62.9 (9.0) 
 
 
65.4 (12.0) 
 
 
64.2 (10.6) 
Resting respiratory 
rate (per minute) 
 
16.6 (6.0) 
 
15.3 (3.4) 
 
15.9 (4.8) 
Pulse Oximetry, % 96.3 (2.1) 97.0 (2.0) 96.7 (2.0) 
NTproBNPc, pg/mL 2169 (1092, 3851) 2851 (1694, 5437) 2598 (1092, 4982) 
a Continuous data is presented as mean (SD) or median (IQR), and categorical data as n (%); 
b NTproBNP conducted by certain sites only 
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Supplementary Table 3 
Data on study drug use is described here, including estimates of number of pills taken as determined 
by number unused and returned. The cases where pills were dispensed but the bottles not returned 
were managed in two ways, assuming: i) that all the pills in that batch were taken; and ii) that none 
were taken. 
The first dose was taken a median of 1 day after randomisation in the morphine group (range 0 to 7), 
and 0.5 days in the placebo group (range 0 to 5). Most first doses were taken in the afternoon 
(morphine group, n=18, 90.0%; placebo group, n=21, 87.5%). 
It was intended for participants to take two IMP capsules a day for 84 days, a total of 168 tablets. 
Estimates of the proportion of tablets taken range from 39% to 51% in the morphine group, and 64% 
to 83% in the placebo group, depending on whether it is assumed that no or all the pills were taken 
in cases where bottles were not returned (Supplementary Table 5).  
Supplementary Table 3: Study drug use by randomised group 
 Morphine/Placebo Docusate/Placebo 
Morphine 
(n=21) 
Placebo 
(n=24) 
Morphine 
(n=21) 
Placebo 
(n=24) 
Dispensed at, n (%): 
Baseline 
Week 4 
Week 8 
 
21 (100.0) 
13 (61.9) 
9 (42.9) 
 
24 (100.0) 
22 (91.7) 
17 (70.8) 
 
21 (100.0) 
13 (61.9) 
9 (42.9) 
 
24 (100.0) 
22 (91.7) 
17 (70.8) 
Total number dispensed 
Mean (SD) 
Median (min, max) 
 
114.7 (51.6) 
 112 (56, 168) 
 
147.0 (36.2) 
 168 (56, 168) 
 
114.7 (51.6) 
 112 (56, 168) 
 
147.0 (36.2) 
 168 (56, 168) 
Assume all pills taken if return pill count missing 
Total number returned 
Mean (SD) 
Median (min, max) 
 
29.8 (24.6) 
37 (0, 91) 
 
17.9 (22.1) 
6 (0, 64) 
 
41.8 (39.5) 
39 (0, 168) 
 
32.1 (41.1) 
12.5 (0, 168) 
Percentage taken of 
drugs taken that were 
dispensed 
Mean (SD) 
Median (min, max) 
 
 
 
59.6 (36.3) 
67.0 (0, 100) 
 
 
 
82.6 (26.4) 
96.4 (5.4, 100) 
 
 
 
52.4 (36.3) 
44.0 (0, 100) 
 
 
 
73.2 (34.1) 
90.9 (0, 100) 
Total used out of 
number intended 
(n=168) 
Mean (SD) 
Median (min, max) 
 
 
 
50.5 (42.0) 
44.6 (0, 100) 
 
 
 
76.9 (31.3) 
96.1 (1.8, 100) 
 
 
 
43.4 (40.4) 
33.3 (0, 100) 
 
 
 
68.4 (36.2) 
86.6 (0, 100) 
Assume no pills taken if return pill count missing 
Total number returned 
Mean (SD) 
Median (min, max) 
 
48.4 (30.6) 
46 (0, 118) 
 
38.9 (42.1) 
32.5 (0, 168) 
 
55.1 (41.0) 
46 (0, 168) 
 
53.1 (51.8) 
43.5 (0, 168) 
Percentage taken of 
drugs taken that were 
dispensed 
Mean (SD) 
Median (min, max) 
 
 
 
48.5 (30.1) 
35.7 (0, 100) 
 
 
 
69.4 (32.8) 
79.5 (0, 100) 
 
 
 
44.5 (31.4) 
33.3 (0, 100) 
 
 
 
59.3 (38.0) 
69.3 (0, 100) 
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Total used out of 
number intended 
(n=168) 
Mean (SD) 
Median (min, max) 
 
 
 
39.4 (33.8) 
33.3 (0, 100) 
 
 
 
64.4 (34.8) 
69.6 (0, 100) 
 
 
 
35.5 (33.9) 
29.8 (0, 100) 
 
 
 
55.9 (39.1) 
64.9 (0, 100) 
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Supplementary Tables 4a and 4b 
Supplementary Table 4a: Serious adverse events 
Serious adverse events Morphine (n=21) 
Placebo 
(n=24) 
Total 
(n=45) 
Number of events 12 15 27 
Number of participants with ≥1 event, 
n (%)a 
 
7 (33.3) 
 
10 (41.7) 
 
17 (37.8) 
Number of events/participant, n (%)b 
1 
2 
3 
4 
 
3 (42.9) 
3 (42.9) 
1 (14.3) 
0 (0.0) 
 
8 (80.0) 
0 (0.0) 
1 (10.0) 
1 (10.0) 
 
11 (64.7) 
3 (17.7) 
2 (11.8) 
1 (5.9) 
Type of event, n (%)c 
Death 
Life-threatening 
Disability/incapacity 
Hospitalisation 
Prolonged hospital stay 
Congenital anomaly 
Otherd 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
10 (83.3) 
0 (0.0) 
0 (0.0) 
2 (16.7) 
 
1 (6.7) 
0 (0.0) 
0 (0.0) 
14 (93.3) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
1 (3.7) 
0 (0.0) 
0 (0.0) 
24 (88.9) 
0 (0.0) 
0 (0.0) 
2 (7.4) 
Severity, n (%)c 
Mild  
Moderate 
Severe 
Missing 
 
0 (0.0) 
7 (58.3) 
2 (16.7) 
3 (25.0) 
 
3 (20.0) 
1 (6.7) 
6 (40.0) 
5 (33.3) 
 
3 (11.1) 
8 (29.6) 
8 (29.6) 
8 (29.6) 
Relatedness to morphine, n (%)c 
Not related 
Unlikely to be related 
Possibly related 
Probably related 
Definitely related 
 
8 (66.7) 
1 (8.3) 
2 (16.7) 
1 (8.3) 
0 (0.0) 
 
12 (80.0) 
2 (13.3) 
0 (0.0) 
1 (6.7) 
0 (0.0) 
 
20 (74.1) 
3 (11.1) 
2 (7.4) 
2 (7.4) 
0 (0.0) 
Relatedness to docusate, n (%)c 
Not related 
Unlikely to be related 
Possibly related 
Probably related 
Definitely related 
 
10 (83.3) 
2 (16.7) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
14 (93.3) 
1 (6.7) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
24 (88.9) 
3 (11.1) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
Expectedness, n (%)e 
Expected 
Not expectedf 
 
2 (66.7) 
1 (33.3) 
 
1 (100.0) 
0 (0.0) 
 
3 (75.0) 
1 (25.0) 
a percentage out of number of randomised participants; b percentages out of number of participants with at 
least one event; c percentage out of number of events; d cognitive decline (n=1); slight deterioration in 
mental health state (n=1); e only if event possibly, probably or definitely related to morphine, percentage 
out of number of these events; f this event was reported to the MHRA as a SUSAR and the participants 
allocation was unblinded to the treating clinician (marked cognitive decline noted whilst performing MoCA 
outcome at week 4 time point).  
 
A total of 54 non-serious adverse events were reported for 26 participants (14 (67%) in the 
morphine group, and 12 (50%) in the placebo group). Half of these participants experienced more 
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than one event (range 1 to 9). Nineteen events were deemed to be at least possibly related to the 
IMP (16 (50%) in the morphine group, and 3 (14%) in the placebo group), of which only one was 
unexpected (participant reported dry month of mild intensity). The most commonly reported events 
were nausea (6 occurrences for 5 morphine participants, and 1 occurrence for 1 placebo 
participant), cognitive disturbance (5 occurrences for 3 morphine participants), and lung infection (1 
occurrence for 1 morphine participant, and 4 occurrences for 4 placebo participants). 
Supplementary Table 4b: Non-serious adverse events 
Non-serious adverse events Morphine (n=21) 
Placebo 
(n=24) 
Total 
(n=45) 
Number of events 32 22 54 
Number of participants with ≥1 
event, n (%)a 
14 (66.7) 12 (50.0) 26 (57.8) 
Number of events/participant, n 
(%)b 
1 
2 
3 
4 
5 
… 
9 
 
 
7 (50.0) 
3 (21.4) 
2 (14.3) 
1 (7.1) 
0 (0.0) 
0 (0.0) 
1 (7.1) 
 
 
6 (50.0) 
4 (33.3) 
1 (8.3) 
0 (0.0) 
1 (8.3) 
0 (0.0) 
0 (0.0) 
 
 
13 (50.0) 
7 (26.9) 
3 (11.5) 
1 (3.9) 
1 (3.9) 
0 (0.0) 
1 (3.9) 
Severity, n (%)c 
Mild  
Moderate 
Severe 
Missing 
 
14 (43.8) 
17 (53.1) 
1 (3.1) 
0 (0.0) 
 
11 (50.0) 
8 (36.4) 
1 (4.6) 
2 (9.1) 
 
25 (46.3) 
25 (46.3) 
2 (3.7) 
2 (3.7) 
Relatedness to IMP, n (%)c 
Not related 
Unlikely to be related 
Possibly related 
Probably related 
Definitely related 
 
11 (34.3) 
5 (15.6) 
9 (28.1) 
5 (15.6) 
2 (6.3) 
 
12 (54.6) 
7 (31.8) 
3 (13.6) 
0 (0.0) 
0 (0.0) 
 
23 (42.6) 
12 (22.2) 
12 (22.2) 
5 (9.3) 
2 (3.7) 
Relatedness to NIMP, n (%)c 
Not related 
Unlikely to be related 
Possibly related 
Probably related 
Definitely related 
 
23 (71.9) 
5 (15.6) 
4 (12.5) 
0 (0.0) 
0 (0.0) 
 
15 (68.2) 
5 (22.7) 
2 (9.1) 
0 (0.0) 
0 (0.0) 
 
38 (70.4) 
10 (18.5) 
6 (11.1) 
0 (0.0) 
0 (0.0) 
Expectedness for IMP, n (%) 
Expected 
Not expected 
Missing 
 
19 (59.4) 
12 (37.5) 
1 (3.1) 
 
5 (22.7) 
15 (68.2) 
2 (9.1) 
 
24 (44.4) 
27 (50.0) 
3 (5.6) 
Expectedness for NIMP, n (%) 
Expected 
Not expected 
Missing 
 
8 (25.0) 
18 (56.2) 
6 (18.8) 
 
3 (13.6) 
17 (77.3) 
2 (9.1) 
 
11 (20.4) 
35 (64.8) 
8 (14.8) 
a percentage out of number of randomised participants; b percentages out of number of participants with at 
least one event; c percentage out of number of events 
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Supplementary Table 5a: Harms by grade, treatment group and time point, up to week 4 
Harm 
symptom 
grade 
Baseline Day 2 Day 4 Day 7 Week 2 Week 3 Week 4 
Morphine Placebo Morphine Placebo Morphine Placebo Morphine Placebo Morphine Placebo Morphine Placebo Morphine Placebo 
Confusion               
0 20 (95.2) 22 (91.7) 19 (95.0) 23 (95.8) 19 (95.0) 24 (100) 19 (95.0) 22 (91.7) 18 (90.0) 22 (91.7) 20 (100) 21 (91.3) 18 (90.0) 21 (91.3) 
1 1 (4.8) 2 (8.3) 1 (5.0) 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.3) 2 (10.0) 2 (8.3) 0 (0.0) 2 (8.7) 2 (10.0) 2 (8.7) 
2+ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Constipation               
0 18 (85.7) 19 (79.2) 13 (65.0) 22 (91.7) 10 (50.0) 22 (91.7) 7 (35.0) 22 (91.7) 14 (70.0) 22 (91.7) 15 (75.0) 22 (95.7) 14 (70.0) 21 (91.3) 
1 3 (14.3) 5 (20.8) 7 (35.0) 2 (8.3) 7 (35.0) 2 (8.3) 9 (45.0) 2 (8.3) 6 (30.0) 2 (8.3) 4 (20.0) 1 (4.3) 6 (30.0) 2 (8.7) 
2+ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (15.0) 0 (0.0) 4 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Vomiting               
0 21 (100) 24 (100) 18 (90.0) 24 (100) 17 (85.0) 24 (100) 16 (80.0) 23 (95.8) 19 (95.0) 24 (100) 18 (90.0) 23 (100) 17 (85.0) 22 (95.7) 
1 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 3 (15.0) 0 (0.0) 3 (15.0) 1 (4.2) 1 (5.0) 0 (0.0) 2 (10.0) 0 (0.0) 2 (10.0) 1 (4.3) 
2+ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 
Nausea               
0 20 (95.2) 23 (95.8) 14 (70.0) 23 (95.8) 12 (60.0) 21 (87.5) 14 (70.0) 21 (87.5) 13 (65.0) 23 (95.8) 16 (80.0) 22 (95.7) 16 (80.0) 18 (78.3) 
1 1 (4.8) 1 (4.2) 5 (25.0) 1 (4.2) 7 (35.0) 2 (8.3) 4 (20.0) 3 (12.5) 7 (35.0) 1 (4.2) 3 (15.0) 1 (4.3) 3 (15.0) 5 (21.7) 
2+ 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 1 (5.0) 1 (4.2) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 1 (5.0) 0 (0.0) 
Memory 
impairment 
              
0 19 (90.5) 18 (75.0) 18 (94.7) 22 (91.7) 19 (95.0) 23 (95.8) 20 (100) 21 (87.5) 19 (95.0) 22 (91.7) 19 (95.0) 21 (91.3) 17 (85.0) 20 (87.0) 
1 2 (9.5) 6 (25.0) 1 (5.3) 2 (8.3) 1 (5.0) 1 (4.2) 0 (0.0) 3 (12.5) 1 (5.0) 2 (8.3) 1 (5.0) 2 (8.7) 3 (15.0) 3 (13.0) 
2+ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Cognitive 
disturbance 
              
0 19 (90.5) 23 (95.8) 20 (100) 23 (95.8) 20 (100) 24 (100) 19 (95.0) 24 (100) 18 (90.0) 23 (95.8) 19 (100) 23 (100) 18 (90.0) 22 (95.7) 
1 2 (9.5) 1 (4.2) 0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 1 (4.2) 0 (0.0) 0 (0.0) 2 (10.0) 1 (4.3) 
2+ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
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Supplementary Table 5b: Harms by grade, treatment group and time point, weeks 8 and 12 
Harm symptom grade Week 8 Week 12 
Morphine Placebo Morphine Placebo 
Confusion     
0 16 (80.0) 21 (91.3) 17 (85.0) 19 (86.4) 
1 3 (15.0) 1 (4.3) 1 (5.0) 3 (13.6) 
2+ 1 (5.0) 1 (4.3) 2 (10.0) 0 (0.0) 
Constipation     
0 15 (75.0) 22 (95.7) 15 (75.0) 17 (77.3) 
1 5 (25.0) 1 (4.3) 4 (20.0) 5 (22.7) 
2+ 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 
Vomiting     
0 18 (90.0) 23 (100.0) 17 (85.0) 21 (95.5) 
1 2 (10.0) 0 (0.0) 2 (10.0) 1 (4.5) 
2+ 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 
Nausea     
0 16 (80.0) 20 (87.0) 12 (60.0) 20 (90.9) 
1 3 (15.0) 1 (4.3) 5 (25.0) 1 (4.5) 
2+ 1 (5.0) 2 (8.7) 3 (15.0) 1 (4.5) 
Memory impairment     
0 17 (85.0) 19 (82.6) 16 (80.0) 18 (85.7) 
1 2 (10.0) 2 (8.7) 2 (10.0) 3 (14.3) 
2+ 1 (5.0) 2 (8.7) 2 (10.0) 0 (0.0) 
Cognitive disturbance     
0 19 (95.0) 22 (95.7) 18 (90.0) 19 (86.4) 
1 0 (0.0) 0 (0.0) 0 (0.0) 3 (13.6) 
2+ 1 (5.0) 1 (4.3) 2 (10.0) 0 (0.0) 
 Supplementary Tables 6a and 6b 
Supplementary Table 6a: EQ-5D-5L, and health service use during previous 4 weeks, at baseline 
and week 4 by randomised group 
EQ-5D-5L, and health service use 
during previous 4 weeks 
Morphine Placebo Total 
Baseline N=21 N=24 N=45 
EQ-5D-5L index value, Mean (SD) 
Median (min, max) 
0.59 (0.15) 
0.63 (0.23, 0.77) 
0.61 (0.20) 
0.65 (0.04, 0.81) 
0.60 (0.17) 
0.64 (0.04, 0.81) 
EQ-5D-5L VAS, Mean (SD) 
Median (min, max) 
51.7 (18.1) 
50 (5, 85) 
55.1 (13.7) 
54 (30, 90) 
53.5 (15.8) 
50 (5, 90) 
Overnight stays in hospital, n (%) 0 (0.0) 2 (8.3) 2 (4.4) 
Total number of nights, Mean (SD) 
Median (min, max) 
- 5.0 (5.7) 
5 (1, 9) 
5.0 (5.7) 
5 (1, 9) 
Outpatient appointment, n (%) 12 (57.1) 14 (58.3) 26 (57.8) 
Total number of visits, Mean (SD) 
Median (min, max) 
1.6 (0.9) 
1 (1, 3) 
1.6 (1.2) 
1 (1, 5) 
1.6 (1.0) 
1 (1, 5) 
Contact with GP, n (%) 12 (57.1) 7 (29.2) 19 (42.2) 
Total number of contacts, Mean (SD) 
Median (min, max) 
1.1 (0.3) 
1 (1, 2) 
1.1 (0.4) 
1 (1, 2) 
1.1 (0.3) 
1 (1, 2) 
Number at surgery, Mean (SD) 
Median (min, max) 
1.0 (0.4) 
1 (0, 2) 
1.1 (0.4) 
1 (1, 2) 
1.1 (0.4) 
1 (0, 2) 
Number at home, Mean (SD) 
Median (min, max) 
0.1 (0.3) 
0 (0, 1) 
0.0 (0.0) 
0 (0, 0) 
0.05 (0.2) 
0 (0, 1) 
Number via telephone, Mean (SD) 
Median (min, max) 
0.0 (0.0) 
0 (0, 0) 
0.0 (0.0) 
0 (0, 0) 
0.0 (0.0) 
0 (0, 0) 
Treatment at A&E department, n (%) 0 (0.0) 3 (12.5) 3 (6.7) 
Total number of visits, Mean (SD) 
Median (min, max) 
- 1.0 (0.0) 
1 (1, 1) 
1.0 (0.0) 
1 (1, 1) 
Contact with a nurse, n (%) 10 (47.6) 11 (45.8) 21 (46.7) 
Total number of contacts, Mean (SD) 
Median (min, max) 
1.7 (0.9) 
1 (1, 3) 
2.1 (1.2) 
2 (1, 4) 
1.9 (1.1) 
1 (1, 4) 
Number at surgery, Mean (SD) 
Median (min, max) 
1.0 (1.1) 
1 (0, 3) 
1.1 (1.1) 
1 (0, 4) 
1.0 (1.1) 
1 (0, 4) 
Number at home, Mean (SD) 
Median (min, max) 
0.3 (0.5) 
0 (0, 1) 
0.9 (1.2) 
1 (0, 4) 
0.6 (1.0) 
0 (0, 4) 
Number via telephone, Mean (SD) 
Median (min, max) 
0.4 (1.0) 
0 (0, 3) 
0.1 (0.3) 
0 (0, 1) 
0.2 (0.7) 
0 (0, 3) 
Week 4 N=20 N=24 N=45 
EQ-5D-5L index value, Mean (SD) 
Medan (min, max) 
0.64 (0.17) 
0.67 (0.16, 0.88) 
0.64 (0.22) 
0.68 (-0.13, 0.91) 
0.64 (0.19) 
0.68 (-0.13, 0.91) 
EQ-5D-5L VAS, Mean (SD) 
Median (min, max) 
50.2 (20.7) 
50 (20, 90) 
58.0 (17.8) 
60 (20, 85) 
54.3 (19.4) 
55 (20, 90) 
Overnight stays in hospital, n (%) 3 (15.0) 2 (8.3) 5 (11.4) 
Total number of nights, Mean (SD) 
Median (min, max) 
4.7 (3.5) 
5 (1, 8) 
5.5 (6.4) 
6 (1, 10) 
5.0 (4.1) 
5 (1, 10) 
Outpatient appointment, n (%) 6 (30.0) 4 (16.7) 10 (22.7) 
Total number of visits, Mean (SD) 
Median (min, max) 
1.7 (0.8) 
2 (1, 3) 
2.0 (1.4) 
2 (1, 4) 
1.8 (1.0) 
2 (1, 4) 
Contact with GP, n (%) 13 (65.0) 10 (41.7) 23 (52.3) 
 Total number of contacts, Mean (SD) 
Median (min, max) 
1.3 (0.6) 
1 (1, 3) 
1.1 (0.3) 
1 (1, 2) 
1.2 (0.5) 
1 (1, 3) 
Number at surgery, Mean (SD) 
Median (min, max) 
0.9 (0.6) 
1 (0, 2) 
1.0 (0.0) 
1 (1, 1) 
1.0 (0.5) 
1 (0, 2) 
Number at home, Mean (SD) 
Median (min, max) 
0.0 (0.0) 
0 (0, 0) 
0.0 (0.0) 
0 (0, 0) 
0.0 (0.0) 
0 (0, 0) 
Number via telephone, Mean (SD) 
Median (min, max) 
0.4 (0.7) 
0 (0, 2) 
0.1 (0.3) 
0 (0, 1) 
0.3 (0.5) 
0 (0, 2) 
Treatment at A&E department, n (%) 3 (15.0) 3 (12.5) 6 (13.6) 
Total number of visits, Mean (SD) 
Median (min, max) 
 1.3 (0.6) 
1 (1, 2) 
1.0 (0.0) 
1 (1, 1) 
1.2 (0.4) 
1 (1, 2) 
Contact with a nurse, n (%) 7 (35.0) 10 (41.7) 17 (38.6) 
Total number of contacts, Mean (SD) 
Median (min, max) 
 2.3 (2.0) 
1 (1, 6) 
1.8 (1.1) 
1 (1, 4) 
2.0 (1.5) 
1 (1, 6) 
Number at surgery, Mean (SD) 
Median (min, max) 
1.1 (1.5) 
1 (0, 4) 
1.3 (1.1) 
1 (0, 3) 
1.2 (1.2) 
1 (0, 4) 
Number at home, Mean (SD) 
Median (min, max) 
1.1 (2.2) 
0 (0, 6) 
0.4 (1.3) 
0 (0, 4) 
0.7 (1.7) 
0 (0, 6) 
Number via telephone, Mean (SD) 
Median (min, max) 
0.0 (0.0) 
0 (0, 0) 
0.0 (0.0) 
0 (0, 0) 
0.0 (0.0) 
0 (0, 0) 
 
Supplementary Table 6b: EQ-5D-5L, and health service use during previous 4 weeks, at weeks 8 
and 12 by randomised group 
EQ-5D-5L, and health service use 
during previous 4 weeks 
Morphine Placebo Total 
Week 8 N=20 N=23 N=43 
EQ-5D-5L index value, Mean (SD) 
Median (min, max) 
0.68 (0.20) 
0.72 (0.24, 1.00) 
0.58 (0.34) 
0.66 (-0.51, 
1.00) 
0.63 (0.29) 
0.68 (-0.51, 1.00) 
EQ-5D-5L VAS, Mean (SD) 
Median (min, max) 
56.5 (20.4) 
52.5 (10, 95) 
54.3 (21.0) 
60 (0, 90) 
55.3 (20.5) 
55 (0, 95) 
Overnight stays in hospital, n (%) 1 (5.0) 5 (21.7) 6 (14.0) 
Total number of nights, Mean (SD) 
Median (min, max) 
11.0 (-) 
11 (11, 11) 
10.0 (10.3) 
7 (1, 26) 
10.2 (9.2) 
9 (1, 26) 
Outpatient appointment, n (%) 5 (25.0) 7 (30.4) 12 (27.9) 
Total number of visits, Mean (SD) 
Median (min, max) 
1.2 (0.4) 
1 (1, 2) 
1.9 (1.1) 
2 (1, 4) 
1.6 (0.9) 
1 (1, 4) 
Contact with GP, n (%) 8 (40.0) 8 (34.8) 16 (37.2) 
Total number of contacts, Mean 
(SD) 
Median (min, max) 
1.8 (0.9) 
1.5 (1, 3) 
1.4 (0.7) 
1 (1, 3) 
1.6 (0.8) 
1 (1, 3) 
Number at surgery, Mean (SD) 
Median (min, max) 
1.3 (0.7) 
1 (0, 2) 
1.3 (0.9) 
1 (0, 3) 
1.3 (0.8) 
1 (0, 3) 
Number at home, Mean (SD) 
Median (min, max) 
0.0 (0.0) 
0 (0, 0) 
0.1 (0.4) 
0 (0, 1) 
0.1 (0.3) 
0 (0, 1) 
Number via telephone, Mean (SD) 
Median (min, max) 
0.5 (1.1) 
0 (0, 3) 
0.0 (0.0) 
0 (0, 0) 
0.3 (0.8) 
0 (0, 3) 
Treatment at A&E department, n 
(%) 
1 (5.0) 3 (13.0) 4 (9.3) 
 EQ-5D-5L, and health service use 
during previous 4 weeks 
Morphine Placebo Total 
Total number of visits, Mean (SD) 
Median (min, max) 
1.0 (-) 
1 (1, 1) 
1.0 (0.0) 
1 (1, 1) 
1.0 (0.0) 
1 (1, 1) 
Contact with a nurse, n (%) 6 (30.0) 7 (30.4) 13 (30.2) 
Total number of contacts, Mean 
(SD) 
Median (min, max) 
3.2 (1.2) 
3 (2, 5) 
1.3 (0.5) 
1 (1, 2) 
2.2 (1.3) 
2 (1, 5) 
Number at surgery, Mean (SD) 
Median (min, max) 
1.7 (0.8) 
1.5 (1, 3) 
0.9 (0.7) 
1 (0, 2) 
1.2 (0.8) 
1 (0, 3) 
Number at home, Mean (SD) 
Median (min, max) 
0.8 (1.0) 
0.5 (0, 2) 
0.3 (0.5) 
0 (0, 1) 
0.6 (0.8) 
0 (0, 2) 
Number via telephone, Mean (SD) 
Median (min, max) 
0.7 (1.0) 
0 (0, 2) 
0.2 (0.4) 
0 (0, 1) 
0.4 (0.8) 
0 (0, 2) 
Week 12 N=20 N=22 N=42 
EQ-5D-5L index value, Mean (SD) 
Median (min, max) 
0.58 (0.21) 
0.63 (0.04, 0.88) 
0.66 (0.17) 
0.67 (0.08, 0.84) 
0.62 (0.19) 
0.66 (0.04, 0.88) 
EQ-5D-5L VAS, Mean (SD) 
Median (min, max) 
55.9 (18.6) 
50 (10, 92) 
59.8 (15.6) 
60 (25, 90) 
57.9 (17.0) 
60 (10, 92) 
Overnight stays in hospital, n (%) 3 (15.0) 3 (13.6) 6 (14.3) 
Total number of nights, Mean (SD) 
Median (min, max) 
12.0 (6.1) 
15 (5, 16) 
4.0 (3.0) 
4 (1, 7) 
8.0 (6.1) 
6 (1, 16) 
Outpatient appointment, n (%) 12 (60.0) 6 (27.3) 18 (42.9) 
Total number of visits, Mean (SD) 
Median (min, max) 
1.6 (1.1) 
1 (1, 4) 
1.2 (0.4) 
1 (1, 2) 
1.4 (0.9) 
1 (1, 4) 
Contact with GP, n (%) 14 (70.0) 6 (27.3) 20 (47.6) 
Total number of contacts, Mean 
(SD) 
Median (min, max) 
1.4 (0.9) 
1 (1, 4) 
1.7 (0.5) 
2 (1, 2) 
1.5 (0.9) 
1 (1, 4) 
Number at surgery, Mean (SD) 
Median (min, max) 
1.1 (0.8) 
1 (0, 3) 
1.5 (0.5) 
1.5 (1, 2) 
1.3 (0.7) 
1 (0, 3) 
Number at home, Mean (SD) 
Median (min, max) 
0.1 (0.3) 
0 (0, 1) 
0.0 (0.0) 
0 (0, 0) 
0.1 (0.2) 
0 (0, 1) 
Number via telephone, Mean (SD) 
Median (min, max) 
0.4 (0.7) 
0 (0, 2) 
0.2 (0.4) 
0 (0, 1) 
0.3 (0.6) 
0 (0, 2) 
Treatment at A&E department, n 
(%) 
4 (20.0) 4 (18.2) 8 (19.1) 
Total number of visits, Mean (SD) 
Median (min, max) 
1.0 (0.0) 
1 (1, 1) 
1.0 (0.0) 
1 (1, 1) 
1.0 (0.0) 
1 (1, 1) 
Contact with a nurse, n (%) 5 (25.0) 9 (40.9) 14 (33.3) 
Total number of contacts, Mean 
(SD) 
Median (min, max) 
1.8 (0.8) 
2.0 (1, 3) 
2.1 (2.3) 
1.0 (1, 8) 
2.0 (1.9) 
1 (1, 8) 
Number at surgery, Mean (SD) 
Median (min, max) 
0.8 (0.4) 
1 (0, 1) 
0.8 (0.7) 
1 (0, 2) 
0.8 (0.6) 
1 (0, 2) 
Number at home, Mean (SD) 
Median (min, max) 
0.8 (1.0) 
0.5 (0, 2) 
1.1 (2.6) 
0 (0, 8) 
1.0 (2.2) 
0 (0, 8) 
Number via telephone, Mean (SD) 
Median (min, max) 
0.0 (0.0) 
0 (0, 0) 
0.2 (0.7) 
0 (0, 2) 
0.2 (0.6) 
0 (0, 2) 
 
 Supplementary Figure 1. 
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